Dosimetry

Localized high dose

Delivered precisely to the tumor. High absorbed dose
Immediate tumor irradiation
Minimal exposure outside implantation site
YntraDose® delivers a high absorbed dose directly within the tumor while minimizing irradiation of surrounding tissues — an immediate, localized effect confirmed by imaging (PET/CT).
PET/CT imaging showing dose distribution within the implant
Mean Dose of the implant 222 Gy
PET/CT imaging showing dose at the implant edge and isodose margin
Mean Dose alongside the edge of implantation 161 Gy Mean tissue dose up to 57 Gy Isodose margin 105 Gy (3-5 mm)
MIM-generated DVH — dose distribution MIM-Generated DVHs 0 20 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460 480 500 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 62 64 66 68 70 72 74 76 78 80 82 84 86 88 90 92 94 96 98 100 102 104 Dose (Gy) Ratio of total structure volume (%) Within the implant — mean 222 Gy Edge of the implant — mean 161 Gy Surrounding tissue — up to 57 Gy

Figures from a GLP safety study conducted in an animal model (24-132-3). YntraDose® is an investigational radiotherapeutic; safety and performance are being evaluated in clinical development and have not been established.

Mechanism of action

Uniquely positioned for the KRAS era

Targeted, localized injection of Yttrium-90 microspheres in a polymerized matrix (the “glue”) — percutaneous, focal and leakage-proof. YntraDose® is designed to address the specific challenges of pancreatic cancer.
PET/CT scan 24 hours after YntraDose implantation, HCC case
24 h post-implantation — PET/CT, HCC
PET/CT scan 24 hours after YntraDose implantation, DCIS case
24 h post-implantation — PET/CT, DCIS

Images from first-in-human studies. YntraDose® is an investigational radiotherapeutic; safety and performance are being evaluated in clinical development and have not been established.

  1. Contorted arterial supply Arterial catheter placement difficulty Percutaneous; focal — no arterial catheter
  2. Disorganised neo-angiogenesis & uncontrolled fibroblast proliferation Intra-arterial catheter administration difficulty Percutaneous; focal delivery
  3. High intra-tumoral pressure: collapsed vasculature Difficult TARE and limited effectiveness of systemic drug therapy; hypoxia Rapid glue polymerisation; leakage-proof; 8–30% v/v ratio
  4. High intra-tumoral pressure: hypoxia Relatively high radiation doses needed; limited SBRT effect High-energy, high-dose radiation (≈100 Gy at implant edge)
  5. Aggressive disease progression Maintain durable local tumor control while systemic therapies control micrometastatic disease First-line add-on to best systemic therapies; fast-acting isotope
  6. Body movement Off-target radiation using SBRT Percutaneous; focal — reduced off-target radiation
  7. Receptor heterogeneity Limited drug effectiveness; drug resistance Physical radiotherapeutic mechanism — no receptor dependency
  8. Comorbidities Need for a minimally invasive approach Minimally invasive; percutaneous; no general anaesthesia
Close